

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/23807860>

The Marine Sponge *Diacarnus bismarckensis* as a Source of Peroxiterpene Inhibitors of *Trypanosoma brucei*, the Causative Agent of Sleeping Sickness

ARTICLE in JOURNAL OF NATURAL PRODUCTS · FEBRUARY 2009

Impact Factor: 3.8 · DOI: 10.1021/np800711a · Source: PubMed

CITATIONS

27

READS

16

7 AUTHORS, INCLUDING:



[Karen Tenney](#)

University of California, Santa Cruz

56 PUBLICATIONS 1,300 CITATIONS

SEE PROFILE



[Michelle Arkin](#)

University of California, San Francisco

90 PUBLICATIONS 4,761 CITATIONS

SEE PROFILE



[Phil Crews](#)

University of California, Santa Cruz

179 PUBLICATIONS 6,166 CITATIONS

SEE PROFILE

Published in final edited form as:

J Nat Prod. 2009 February 27; 72(2): 218–222. doi:10.1021/np800711a.

The Marine Sponge, *Diacarnus bismarckensis*, as a Source of Peroxiterpene Inhibitors of *Trypanosoma brucei*, the Causative Agent of Sleeping Sickness

Brent K. Rubio[†], Karen Tenney[†], Kean-Hooi Ang[§], Maha Abdulla[‡], Michelle Arkin[§], James H. McKerrow[‡], and Phillip Crews^{*,†}

Department of Chemistry and Biochemistry and Institute for Marine Sciences, University of California Santa Cruz, Santa Cruz, California 95064, Sandler Center for Basic Research in Parasitic Disease, University of California San Francisco, San Francisco, CA 94143, and Small Molecule Discovery Center, University of California San Francisco, San Francisco, CA 94158

Abstract

Human African trypanosomiasis (HAT), also known as African sleeping sickness, is a neglected tropical disease with inadequate therapeutic options. We have launched a collaborative new lead discovery venture using our repository of extracts and natural product compounds as input into our growth inhibition primary screen against *Trypanosoma brucei*. Careful evaluation of the spectral data of the natural products and derivatives allowed for the elucidation of the absolute configuration (using the modified Mosher's method) of two new peroxiterpenes: (+)-muqubilone B (**1a**) and (–)-ent-muqubilone (**3a**). Five known compounds were also isolated: (+)-sigmosceptrellin A (**4a**), (+)-sigmosceptrellin A methyl ester (**4b**), (–)-sigmosceptrellin B (**5**), (+)-epi-muqubillin A (**6**) and (–)-epi-nuapapu B methyl ester (**7**). The isolated peroxiterpenes demonstrated activities in the range from IC₅₀ = 0.2 – 2 µg/mL.

The search for chemotherapeutics to treat human African trypanosomiasis (HAT), also known as African sleeping sickness, has not been a major target of industry drug discovery campaigns, even though the currently available therapeutics are inadequate.¹ This is surprising as there are 50,000 annual cases of infection, HAT is the world's third most devastating parasitic disease, and it remains a major threat to more than 60 million people.^{2–4} Because it is a serious health problem for resource poor regions of Africa, HAT is designated as a neglected tropical disease (NTD). The causative agent is a protozoan parasite, *Trypanosoma brucei*,⁵ subdivided in two sub-genera, *T. brucei gambiense* in West Africa and *T. brucei rhodesiense* in East Africa. Most of the four current chemotherapeutics to combat these parasites at their different development stages are very antiquated. The drugs (by registration date for HAT treatment) consist of suramin⁴ (1922), pentamidine¹ (1941), melarsoprol³ (1949), and eflorithine¹ (1990). Another relevant point is that new strains of *T. brucei* are showing cross-resistance to some of these agents.⁶ In recent years, only one compound, DB289⁷ (a synthetic analog of pentamidine), received serious clinical evaluation against HAT, but further development was discontinued in 2008.³

*To whom correspondence should be addressed. phil@chemistry.ucsc.edu. Tel: (831) 459-2603. Fax: (831) 459-2935.

[†]University of California, Santa Cruz

[‡]Sandler Center BRPD: University of California, San Francisco


[§]SMDC: University of California, San Francisco

Supporting Information Available: NMR and MS spectra, sponge photographs, isolation scheme and table of optical rotations and absolute configurations of known norterpene peroxides. This material is available free of charge via the Internet at <http://pubs.acs.org>.

The quest to discover antiparasitic lead structures has rarely focused on the chemical diversity inherent in marine natural products. Alternatively, recent studies have used combinatorial chemistry libraries of purine² and thiosemicarbazone⁵ derived structures to seek inhibitors of different *T. brucei* targets.^{2,5} In the early 1990's the University of California Santa Cruz group participated in a collaborative effort with Syntex (with Dr. T. Mathews) to explore marine natural products for their potential to provide anthelmintic lead structures,⁸ but unfortunately these efforts were prematurely suspended. In this context there is a rather attention-grabbing report showing that psammaplin A,⁹ first isolated from the marine sponge *Psammaplysilla* in 1987 and found to possess anthelmintic activity (against *Nippostrongylus brasiliensis*),⁸ was recently found to be active against *T. brucei* (EC₅₀ = 2.6 μ M).¹⁰ Inspired by this recent development, we have launched a new collaborative lead discovery venture using our repository of extracts and natural product compounds as input into our growth inhibition primary screen against *T. brucei*. We were encouraged to continue this effort because of an assay hit from the sponge, *Diacarnus bismarckensis*, which was available in large amounts. The current literature shows over two dozen peroxiterpenes¹¹ reported from *Diacarnus* taxon and these have been primarily evaluated in anticancer screens.¹² Reported in this account are our efforts to isolate and define the total structures of the active principles, presumed to be peroxiterpenes, followed by further biological activity study.

Results and Discussion

Once the decision was made to select the *T. brucei* assay active crude extracts from *D. bismarckensis* (coll. no. 03512), the next step was to employ bioassay-guided fractionation. Although the methanol crude extract partition (XFM, 2.06 g, IC₅₀ = 5.0 μ g/mL) showed good activity, the hexanes (XFH, 8.80 g, IC₅₀ = 0.02 μ g/mL) and dichloromethane (XFD, 0.66 g, IC₅₀ = 0.3 μ g/mL) partitions were selected for further study due to their higher potencies. Analysis of their respective ¹³C NMR spectra confirmed the presence of peroxiterpenes because of prominent resonances in the region δ_C 80 – 82. Orthogonal chromatography facilitated the isolation work, beginning with silica gel flash chromatography followed by reversed phase HPLC, which eventually afforded seven peroxiterpene compounds. The XFH, provided a mixture of 1a, related to (+)-muquibilone/aikupikoxide A (**2**),^{13,14} and (–)-ent-muquibilone (**3a**), an unreported enantiomer of **2**. Preparation of their respective methyl esters was required in the final purification of these compounds. Five additional compounds came from the XFH including (+)-sigmosceptrellin A (**4a**),^{15,16} (+)-sigmosceptrellin A methyl ester (**4b**),^{15,16} (–)-sigmosceptrellin B (**5**),¹⁶ (+)-epi-muquibilin A (**6**),^{12a} and (–)-epi-nuapapuina B methyl ester (**7**).^{12a} The XFD was also a source of four pure compounds: **1a**, **4a**, **5**, and **6**. We obtained all compounds as free carboxylic acids, with the exception that minor quantities of methyl ester **4b** and **7** that are most likely artifacts of isolation. The known compounds (**4** – **7**) have also been previously obtained from sponges classified as *Diacarnus* sp.¹⁷



The structure elucidation of the new compound, (+)-muqubilone B (**1a**), $C_{24}H_{40}O_6$, was initiated by using the characteristic ^{13}C NMR shifts at $\delta_C = 81.2$ (CH) and 80.0 (C) to indicate the presence of a peroxide functionality with trisubstitution (Table 1).¹⁸ Distinct NMR signals for a carboxylic acid ($\delta_C = 178.6$), an acetyl group ($\delta_C = 209.1, 29.8$), an isolated ketone ($\delta_C = 215.4$), a trisubstituted double bond ($\delta_C = 124.6, 134.4$), the molecular formula obtained from the HR-ESI-MS, and dereplication insights, all supported that **1** was a norsesterterpene containing an endoperoxide ring. Another diagnostic NMR signal was that of an isochronous gem-dimethyl functionality ($\delta_C = 24.3$; $\delta_H = 1.13$). At this point it was evident that the C_3 containing carboxylate and the C_{16} acyclic side chains were similar to that of **2**.^{13,14} The side-by-side comparison of the similarities and differences in the NMR data between **1a** and **2** plus the 2D NMR data of the former (Figure 1) unequivocally confirmed that this pair had identical planar structures and must be diastereomers.

Establishing the complete absolute configuration of **1a**, while reasonably straightforward, required a multi-step analysis. The *E* double bond geometry was confirmed by the NOE data shown in Figure 1 (correlation from H-9 to H₂-11) and the characteristic C-22 shift.¹⁹ We have previously used the empirical observations laid out by Capon and MacLeod¹⁸ to set the relative configuration at each of the three chiral centers of the molecular fragment present in *Diacarnus* derived peroxiterpenes and repeated this process here,^{12a} but it first required the preparation of the methyl ester **1b** to obtain a data set consistent with the models.²⁰ The carbon substituent at C-3 was set as equatorial because H-3 exhibited vicinal axial coupling to H-4,

$J_{3,4} = 8.0$ Hz ($J = 3 - 4$ Hz is expected for equatorial). The methyl at C-6 ($\delta_C = 24.2$) was next assigned as equatorial because of its diagnostic ^{13}C NMR shift ($\delta_{C,eq} = 23.5 - 24.0$; $\delta_{C,ax} = 20.5 - 20.9$). Finally the erythro (R^*/R^*) configuration at C-2/C-3 was designated based on the proton chemical shift position at H₃-20, δ_H 1.14 (standard values: $\delta_{H,erythro} = 1.13 - 1.14$; $\delta_{H,threo} = 1.22 - 1.24$).¹⁸ The resulting all R^* configuration at each of the chiral centers confirmed that **1a** ($[\alpha]_D^{28} = +60$) was an unreported diastereomer of **2**, whose relative configuration were previously independently reported as $2R^*$, $3S^*$, $6R^*$ for both (+) muquibilone ($[\alpha]_D^{25} = +48$)¹³ and aikupikoxide A ($[\alpha]_D^{20} = +81$).¹⁴

We next concluded it was essential to push forward and ascertain the absolute configuration of **1a** with the expectation such findings could provide similar insights for **2**. Hydrogenation of **1b**²¹ afforded diol **8** that was further transformed into Mosher's esters **9a** and **9b** as shown in Scheme 1.^{21,22} The circumstance that the Δ^9 double bond was also reduced during the hydrogenation did not affect the outcome in evaluating the $\Delta\delta$ values ($\delta_S - \delta_R$) to verify C-3 as R . Thus, the $2R$, $3R$, $6R$ final absolute configuration is now assigned for (+)-muquibilone **B** (**1a**). It is notable that (+)- $2R$, $3R$, $6R$ -epi-muquibilin A^{12a} (**6**) ($[\alpha]_D^{28} = +59$) also isolated from this sponge represents an obvious biosynthetic precursor of (+)-**1a**, especially in view of their identical chirality. Our further discussion on the absolute configuration of **2** shown here as $2S$, $3R$, $6S$ will accompany the characterization of **3** which follows next.

Noted above was that the XFH provided a mixture of **1a** and an additional new compound (–)-ent-muquibilone (**3a**). The separation of these compounds was accomplished by first subjecting the mixture to methylation using TMS-diazomethane followed by isocratic HPLC purification to cleanly afford **1b** ($[\alpha]_D^{28} = +58$) and **3b** ($[\alpha]_D^{28} = -47$) in a 2:1 ratio. The absolute stereostructure assigned for **3a** was based on data obtained for **3b** using the process parallel to that described above for **1**. Both **1b** and **3b** possessed identical molecular formulas and afforded nearly identical NMR shifts with **2**.¹³ The following observations of H-3, $J_{ax} = 8.0$ Hz; CH₃-21, $\delta_{C,ax} = 20.9$; CH₃-20, $\delta_{H,threo} = 1.25$ indicated that the relative configurations reported for **3b** were equivalent with that of **2**, but these compounds possessed opposite rotation data (see above) and must be enantiomers. A review of the current literature (see Table S1, Supporting Information)^{16,18,23} affirms that the variations in the absolute configurations at C-2 and C-6 within the peroxide containing substructure comprised of the chain from C-1 to C-6 do not influence the rotation sign. Additionally, the sign of optical rotation does not change upon substitution of the free carboxylate. Thus, the absolute configuration at C-3 can be used as an empirical anchor point. For example, when H-3 is in the axial orientation, a (–) $[\alpha]_D$ is observed for $3S$ configuration and the (+) rotation is observed for $3R$ (in CHCl₃). Consequently, the compound (–)-**3b** can be concluded to have the stereostructure of $2R$, $3S$, $6R$. Furthermore (+)-muquibilone/aikupikoxide A^{13,14} (**2**), whose rotation data were discussed above, can be assigned as $2S$, $3R$, $6S$.

The peroxiterpenes isolated in this work and evaluated against *T. brucei* can be grouped into four structural types based simply on the side-chain attached at C-6 of the 1,2-dioxane ring. The first three types each have the C₁₆ carbon side chain that is either acyclic (**1** – **3**), monocyclic (**6**), or bicyclic (**4** – **5**). The final type (**7**) has a C₁₁ monocyclic carbon side chain. The muquibilones (**1a**, **1b**, **3b**) showed similar bioactivities independent of the nature of the carboxylate: free acid (**1a**, IC₅₀ = 2 µg/mL) or methyl ester **1b** (IC₅₀ = 5 µg/mL) and **3b** (IC₅₀ = 3 µg/mL). Consistent with the supposition that bioactivity hinges on the presence of the 1,2-dioxane ring was that diol **8** (IC₅₀ > 25 µg/mL) prepared from **1b** was inactive. A change in the side chain to that containing either a monocyclic or bicyclic ring imparts a barely observable change as shown by the data for sigmosceptrellin A (**4a**, IC₅₀ = 1 µg/mL) and its methyl ester (**4b**, IC₅₀ = 2 µg/mL), sigmosceptrellin B (**5**, IC₅₀ = 0.2 µg/mL), and epi-muquibilin

A (**6**, $IC_{50} = 0.9 \mu\text{g/mL}$). Finally, the length of the side chain does not greatly influence the activity as shown by epi-nuapapu B methyl ester (**7**, $IC_{50} = 2 \mu\text{g/mL}$).

It is relevant to overlay our observations with those from recent studies involving 1,2-dioxane ring containing terpenoids or polyketides and somewhat analogous peroxide ring compounds studied by others. An investigation of *Diacarnus megaspinorhabdosa* afforded a series of peroxiterpenes and one diol product with structures parallel to those reported here.¹² There were varying EC_{50} cytotoxicity effects observed from the evaluation of these compounds against three cancer cell lines and those possessing a C_{16} side chain at C-6 were generally more cytotoxic than those with a C_{11} appendage. Curiously, the one natural product evaluated where the peroxide ring was not present, but replaced by a diol, displayed mild activity against one cell line and inactivity against the other two cell types. In another study, the cytotoxic and antiparasitic properties were compared for 1,2-dioxane and furan ketides isolated from the sponge *Plakortis angulospiculatus*.²⁴ These results showed that both heterocyclic ring types displayed modest cytotoxicity effects while one of the 1,2-dioxane structures potently inhibited *Leishmania chagasi* and *Trypanosoma cruzi*. These preceding literature findings, and those not discussed here showing that other polyketide 1,2-dioxanes have antileishmanial activity,²⁵ alongside our results together suggest that the polyalkylated 1,2-dioxane frameworks are of promise for further development as lead structures. In addition, the therapeutic index of antiparasitic to cytotoxicity action for these structures is in the correct direction.

The responses of *Trypanosoma brucei rhodesiense* have been evaluated for two other sets of peroxide containing structures as follows. The wormwood tree peroxisquiterpene, artemisinin, exhibits nM action against *Plasmodium falciparum*.²⁶ This compound (*T. b. rhodesiense* $IC_{50} = 627$ or $25^{26} \mu\text{g/mL}$) and its close analog deoxyartemisinin (*T. b. rhodesiense* $IC_{50} = 3426$) possess similar mild activity against *T. b. rhodesiense* and the latter, devoid of the cyclic peroxide functionality, is inactive vs. *P. falciparum*. A similar SAR activity pattern is shown for another matched set. This includes the 1,2,4-trioxolane containing synthetic polycyclic OZ277 (*T. b. rhodesiense* $IC_{50} = 0.6 \mu\text{g/mL}$)²⁶ vs. the 1,3-dioxolane containing synthetic polycyclic carbaOZ277 (*T. b. rhodesiense* $IC_{50} = 0.9 \mu\text{g/mL}$)²⁶ which are equipotent against *T. b. rhodesiense* (and have not been tested vs. *P. falciparum*). Overall, it would appear that structural features of **5** (*T. brucei* $IC_{50} = 0.2 \mu\text{g/mL}$) would be an excellent starting point for further SAR modifications as it showed similar potencies on par with a current HAT therapeutic, pentamidine (*T. b. rhodesiense* $IC_{50} = 0.4 \mu\text{g/mL}$).²⁷

Conclusions

This study has revealed new dimensions to the structural and biological activity properties of peroxiterpenes isolated from *Diacarnus* sponges. First, careful evaluation of the spectral data of the natural products and derivatives allowed for the elucidation of the absolute configuration of compounds we isolated including **1a** and **3a** plus a proposal for the absolute configuration of **2**. Secondly, the observation of enantiomeric structures (**2** vs. **3**) from the same genus, *Diacarnus*, but different species from different oceans (**2** from a Red Sea specimen, *D. erythaeus* and **3** from the Indo-Pacific specimen *D. bismarckensis*) is a stunning and rare observation in marine natural products chemistry. Thirdly, we have further demonstrated the value in vigorously considering peroxiterpenes, especially the known compound, (–)-sigmosceptrellin B (**5**) as template for the development of therapeutic leads against *T. brucei*.

Experimental Section

General Experimental Procedures

All NMR experiments were run on Varian UNITY 500 (500 and 125 MHz for ^1H and ^{13}C , respectively) and Varian INOVA 600 spectrometers (600 and 150 MHz for ^1H and ^{13}C ,

respectively) using standard pulse sequences with residual solvent protons and carbons as references (CDCl₃: 7.27 and 77.23 ppm for ¹H and ¹³C, respectively). Mass measurements were obtained on a bench top Mariner ESI-TOF-MS. Crude extractions were obtained using an Accelerated Solvent Extractor (1500 psi, 100 °C, 25 min). Flash chromatography was done on a CombiFlash, using prepacked 40 g silica columns. HPLC was performed with Phenomenex Synergi RP-Max preparative (10 µm, C18, 21.2 mm × 250 mm) and Luna semipreparative (5 µm, C18, 10 mm × 250 mm) columns.

Collection and Identification

The sponge materials were collected in December 2003 by SCUBA at a depth range of 31 – 40 ft near Sanaroa, Papua New Guinea (GPS = 9° 37.214 S: 150° 57.332 E). The sponge samples were ramose in shape with very small oscules throughout and had a purple colored endosome with a grey colored ectosome. The collection was identified as *Diacarnus bismarckensis* (Kelly-Borges & Vacelet, 1995) by Dr. R. W. M. van Soest. Voucher samples have been deposited at UCSC and the Zoological Museum of Amsterdam (UCSC coll. no. 03512 = ZMAPOR 18576). Photographs are also available from the Crews laboratory.

Extraction and Isolation of 03512

Following standard Crews laboratory field protocol, the sponge was soaked for over 24 hours in an ethanol:seawater (1:1) preservative solution which was discarded in the field. The samples were then packed in bottles and shipped to UCSC where the sponge was cut into 1.5 inch segments and dried under air for 2 days. 73.4 g of dried sponge was extracted using an accelerated solvent extractor (ASE) (100° C, 1500 psi, 25 min) to yield hexanes (XFH, 8.80 g), CH₂Cl₂ (XFD, 0.6615 g), and CH₃OH (XFM, 2.06 g) crude extracts. A bioassay guided fraction then followed on the XFH and XFD fractions. The large quantity of XFH crude warranted a further Kupchan-like solvent partition to yield hexanes (XFH₂FH, 4.08 g), CH₂Cl₂ (XFH₂FD, 4.08 g) and CH₃OH (XFH₂FM, 0.518 g) fractions. The XFH₂FH crude was subjected to normal phase automated flash chromatography using a linear gradient on silica gel (CH₂Cl₂ to CH₃OH, 40 min) yielding 6 fractions (XFH₂FHC1 – XFH₂FHC6). An orthogonal chromatographic approach was used on the C3 (1.10 g) and C4 (942 mg) fractions with reversed-phase preparative HPLC (80% aq to 100% CH₃CN linear gradient, 0.1% formic acid, 20 min, ELSD) followed by semipreparative HPLC (70% aq CH₃CN isocratic, 0.1% formic acid, UV = 200 nm). From these fractions, (–)-epi-nuapapuina B methyl ester^{12a} (**7**, 2.9 mg), (+)-sigmosceptrellin A^{15,16} (**4a**, 68.6 mg), (–)-sigmosceptrellin B¹⁶ (**5**, 33.8 mg), (+)-epi-muquibillin A^{12a} (**6**, 23.9 mg) and (+)-sigmosceptrellin A methyl ester^{15,16} (**4b**, 8.2 mg) were isolated. The XFH₂FD was treated in a similar manner to yield a 2:1 mixture (21.4 mg) of (+)-muquibilone B (**1a**) and (–)-ent-muquibilone (**3a**) which were separable after methyl esterification and HPLC (isocratic 85% aq CH₃CN, 0.1% formic acid, UV = 200 nm). The XFD crude fraction was subjected to orthogonal chromatography as previously described. These fractions yielded (+)-muquibilone B (**1a**, 14.3 mg), (+)-sigmosceptrellin A^{15,16} (**4a**, 34.3 mg), (–)-sigmosceptrellin B^{12a} (**5**, 6.1 mg), and (+)-epi-muquibillin A^{12a} (**6**, 6.9 mg).

Trypanosoma brucei brucei Assay

Trypanosoma brucei brucei strain 221 was grown in complete HMI-9 medium containing 10% FBS, 10% Serum Plus medium (Sigma Inc. St. Louis Mo. USA) and 1X penicillin/streptomycin. The trypanosomes were diluted to 1×10⁵ per mL in complete HMI-9 medium. 95 µL per well of the diluted trypanosomes was added to sterile Greiner 96-well flat white opaque culture plates that contained 5 µL of test samples (in 10% DMSO). Control wells contained 95 µL of the diluted trypanosomes and 5 µL of 10% DMSO while control wells for 100% inhibition contained 95 µL of the diluted trypanosomes and 5 µL of 1 mM thimerosal (in 10% DMSO). Trypanosomes were incubated with test samples for 48 h at 37 °C with 5%

CO₂ before monitoring viability. Trypanosomes were then lysed in the wells by adding 50 μ L of CellTiter-Glo™ (Promega Inc., Madison, WI, USA). Lysed trypanosomes were placed on an orbital shaker at room temperature for 2 min. The resulting ATP-bioluminescence of the trypanosomes in the 96-well plates was measured at room temperature using an Analyst HT plate reader (Molecular Devices, Sunnyvale, CA, USA). All IC₅₀ curve fittings were performed with Prism 4 software (GraphPad, San Diego, CA).

(+)-Muquibilone B (1a)

A clear oil; $[\alpha]_D^{28} = +59.5$ ($c = 0.046$, CHCl₃); NMR on Table 1; HR-ESI-MS 425.2934 [M + H]⁺ (calcd for C₂₄H₄₁O₆, 425.2898).

(+)-Sigmosceptrellin A (4a)

Physical data in accordance with published data.^{15,18}

(+)-Sigmosceptrellin A methyl ester (4b)

Physical data in accordance with published data.^{15,18}

(-)-Sigmosceptrellin B (5)

Physical data in accordance with published data.^{16,18}

(+)-Epi-muquibilin A (6)

Physical data in accordance with published data.^{12a}

(-)-Epi-nuapapuina B methyl ester (7)

Physical data in accordance with published data.^{12a}

Methylation of (+)-muquibilone B (1a)

6.5 mg of (+)-muquibilone B (**1a**) was dissolved into 1 mL of CH₃OH to which 2 mL of trimethylsilyldiazomethane (2M in hexanes) was added and stirred at room temperature for 30 min. The solvent was evaporated under nitrogen and the reaction mixture was purified by HPLC (C18 column, 85% aq CH₃CN isocratic, UV = 200 nm) to yield 6.2 mg of (+)-muquibilone B methyl ester (**1b**). **1b**: $[\alpha]_D^{28} = +57.6$ ($c = 0.011$, CHCl₃); ¹H NMR (CDCl₃, 500 MHz) δ_H 1.11 (3H, s, H₃-21), 1.12 (6H, s, H₃-23, H₃-24), 1.14 (3H, d, $J = 7.5$ Hz, H₃-20), 1.41 (2H, m, H₂-7), 1.47 (2H, m, H₂-16), 1.55 (2H, m, H₂-15), 1.62 (3H, d, $J = 1$ Hz, H₃-22), 1.63 (2H, m, H₂-5), 1.76 (1H, dtd, $J = 13, 4.5, 2.5$ Hz, H_{eq}-4), 1.85 (1H, dtd, $J = 13, 8, 4.5$ Hz, H_{ax}-4), 1.94 (1H, m, H_b-8), 2.04 (1H, m, H_a-8), 2.13 (3H, s, H₃-19), 2.21 (2H, t, $J = 8$ Hz, H₂-11), 2.41 (2H, t, $J = 7$ Hz, H₂-17), 2.55 (2H, t, $J = 8$ Hz, H₂-12), 2.58 (1H, quint., $J = 7.5$ Hz, H-2), 3.70 (3H, s, OCH₃), 4.24 (1H, ddd, $J = 8.0, 7.5, 4.5$ Hz, H-3), 5.16 (1H, tq, $J = 6.5$ Hz, 1, H-9); ¹³C NMR (CDCl₃, 125 MHz) δ_C 13.1 (CH₃-20), 16.3 (CH₃-22), 19.2 (CH₂-16), 22.3 (CH₂-8), 22.9 (CH₂-4), 24.2 (CH₃-21), 24.6 (CH₃-23), 24.6 (CH₃-24), 30.2 (CH₂-7), 32.7 (CH₃-11), 33.7 (CH₂-19), 35.0 (CH₂-12), 35.9 (CH₂-5), 39.4 (CH₂-15), 42.9 (CH-2), 44.2 (CH₂-17), 44.2 (C-14), 52.2 (O-CH₃), 80.1 (C-6), 81.5 (CH-3), 124.8 (CH-9), 134.6 (C-10), 174.6 (C-1), 208.8 (C-18), 215.4 (C-13); HR-ESI-MS m/z 461.2906 [M + Na]⁺ (calc. for C₂₅H₄₂O₆Na, 461.2874).

Hydrogenation of (+)-muquibilone B methyl ester (1b)

4 mg of (+)-muquibilone B methyl ester (**1b**) was dissolved into 2 mL of ethanol. 10 mg of palladium on carbon was then added and the slurry was stirred under 1 atm of H₂ for 1 hr at room temperature. The reaction mixture was quenched with water and the palladium catalyst

was filtered through Celite to afford 4 mg of (+)-muqubilone B diol (**8**). **8**: $[\alpha]_D^{28} = +1.7$ ($c = 0.017$, CHCl_3); ^1H NMR (CDCl_3 , 500 MHz) δ_{H} 0.87 (3H, d, $J = 6.5$ Hz, H_3 -22), 1.11 (6H, s, H_3 -23, H_3 -24), 1.16 (3H, s, H_3 -21), 1.21 (3H, d, $J = 7$ Hz), 1.30 (2H, m, H_2 -8), 1.37 (1H, m, H_b -5), 1.40 (2H, m, H_2 -11), 1.43 (1H, m, H_b -15), 1.44 (2H, m, H_2 -7), 1.45 (2H, m, H_2 -16), 1.46 (1H, m, H_a -15), 1.50 (1H, m, H_a -5), 1.59 (1H, m, H_b -9), 1.60 (1H, m, H_a -10), 1.66 (1H, m, H_a -9), 1.67 (1H, m, H_a -4), 2.13 (3H, s, H_3 -19), 2.41 (2H, t, $J = 6.5$ Hz, H_2 -17), 2.46 (2H, t, $J = 8.5$ Hz, H_2 -12), 2.56 (H, quint., $J = 7$ Hz, H-2), 3.70 (H, ddd, $J = 8, 6, 2$ Hz, H-3), 3.72 (3H, s, O- CH_3); ^{13}C NMR (CDCl_3 , 125 MHz) δ_{C} 14.5 (CH_3 -20), 19.2 (CH_3 -22), 19.8 (CH_2 -16), 21.5 (CH_2 -8), 24.6 (CH_3 -23), 24.6 (CH_3 -24), 27.1 (CH_3 -21), 29.0 (CH_2 -4), 30.1 (CH_3 -19), 30.9 (CH-10), 32.6 (CH_2 -11), 34.7 (CH_2 -12), 37.6 (CH_2 -9), 39.5 (CH_2 -15), 42.3 (CH_2 -7), 42.6 (CH_2 -5), 44.1 (CH_2 -17), 45.5 (CH-2), 47.7 (C-14), 52.0 (O- CH_3), 72.6 (C-6), 74.0 (CH-3), 176.7 (C-1), 208.9 (C-18), 216.1 (C-13); HR-ESI-MS m/z 465.3224 $[\text{M} + \text{Na}]^+$ (calc. for $\text{C}_{25}\text{H}_{46}\text{O}_6\text{Na}$, 465.3192).

(R)- and (S)-MTPA esterification of (+)-muqubilone B diol (**8**)

2 mg of (+)-muqubilone B diol (**8**) was dissolved in 200 μL of dry pyridine to which 15 μL of (–)-(*R*)-MTPA-Cl was added. This was stirred at room temperature, under nitrogen, overnight. After the solvent was evaporated under nitrogen, the reaction mixture was purified by HPLC (C18 column, 85% aq CH_3CN isocratic, UV = 254 nm) to yield 1.8 mg of (*S*)-MTPA ester (**9a**). Similarly, 1.8 mg of the diol (**8**) was derivatized with (+)-(*S*)-MTPA-Cl to afford 1.7 mg of the (*R*)-MTPA ester (**9b**). **9a**: ^1H NMR (CDCl_3 , 500 MHz) δ_{H} 0.863 (3H, d, $J = 6$ Hz, H_3 -22), 1.110 (3H, s, H_3 -21), 1.117 (6H, s, H_3 -23, H_3 -24), 1.126 (3H, d, $J = 6$ Hz, H_3 -20), 2.123 (3H, s, H_3 -19), 2.410 (2H, t, $J = 6.5$ Hz, H_2 -17), 2.855 (2H, t, $J = 6.5$ Hz, H_2 -12), 2.855 (H, quint., $J = 7$ Hz, H-2), 3.522 (3H, s, MTPA-O- CH_3), 3.586 (3H, s, O- CH_3), 5.394 (H, td, $J = 7.5, 4$ Hz, H-3), 7.425 (4H, m, MTPA-Ar), 7.561 (1H, m, MTPA-Ar); ESI-MS m/z 681 $[\text{M} + \text{Na}]^+$. **9b**: ^1H NMR (CDCl_3 , 500 MHz) δ_{H} 0.873 (3H, d, $J = 6.5$ Hz, H_3 -22), 1.036 (3H, s, H_3 -21), 1.121 (6H, s, H_3 -23, H_3 -24), 1.186 (3H, d, $J = 7.5$ Hz, H_3 -20), 2.125 (3H, s, H_3 -19), 2.413 (2H, t, $J = 6.5$ Hz, H_2 -17), 2.467 (2H, t, $J = 6.5$ Hz, H_2 -12), 2.865 (1H, quint., $J = 7.5$ Hz, H-2), 3.540 (3H, s, MTPA-O- CH_3), 3.644 (3H, s, O- CH_3), 5.382 (1H, td, $J = 7.5, 4$ Hz, H-3), 7.428 (4H, m, MTPA-Ar), 7.560 (1H, m, MTPA-Ar); ESI-MS m/z 681 $[\text{M} + \text{Na}]^+$.

Methylation of (–)-ent-muqubilone (**3a**)

5 mg of an inseparable mixture of (+)-muqubilone B (**1a**) and (–)-ent-muqubilone (**3a**) (2:1) was dissolved into 1 mL of CH_3OH to which 2 mL of trimethylsilyldiazomethane (2 M in hexanes) was added and stirred at room temperature for 30 min. The solvent was evaporated under nitrogen and the reaction mixture was purified by HPLC (C18 column, 85% aq CH_3CN isocratic, UV = 200 nm) to yield 3.2 mg of (+)-muqubilone B methylester (**1b**) and 1.6 mg of (–)-ent-muqubilone methyl ester (**3b**). **3b**: $[\alpha]_D^{28} = -47$ ($c = 0.004$, CHCl_3); ^1H NMR (CDCl_3 , 500 MHz) δ_{H} 1.11 (6H, s, H_3 -23, H_3 -24), 1.25 (3H, d, $J = 7.0$ Hz, H_3 -20), 1.29 (3H, s, H_3 -21), 1.41 (2H, m, H_2 -16), 1.44 (2H, m, H_2 -7), 1.47 (2H, m, H_2 -15), 1.60 (3H, s, H_3 -22), 1.63 (2H, m, H_2 -5), 1.71 (2H, m, H_2 -4), 2.00 (2H, m, H_2 -8), 2.13 (3H, s, H_3 -19), 2.20 (2H, t, $J = 8.0$ Hz, H_2 -11), 2.41 (2H, t, $J = 7.0$ Hz, H_2 -17), 2.54 (2H, t, $J = 8.0$ Hz, H_2 -12), 2.66 (1H, q, $J = 7.5$ Hz, H-2), 3.70 (3H, s, O- CH_3), 4.12 (1H, ddd, $J = 8.0, 7.5, 4.5$ Hz, H-3), 5.10 (1H, t, $J = 7.0$ Hz, H-9); ^{13}C NMR (CDCl_3 , 125 MHz) δ_{C} 13.8 (CH_3 -20), 16.3 (CH_3 -22), 19.2 (CH_2 -16), 20.9 (CH_3 -21), 21.9 (CH_2 -8), 23.7 (CH_2 -4), 24.5 (CH_3 -23), 24.5 (CH_3 -24), 30.1 (CH_3 -19), 32.2 (CH_2 -5), 33.7 (CH_2 -11), 35.8 (CH_2 -12), 39.4 (CH_2 -15), 39.8 (CH_2 -7), 43.2 (CH-2), 44.1 (CH_2 -17), 47.7 (C-14), 52.7 (O- CH_3), 80.3 (C-6), 81.6 (CH-3), 124.6 (CH-9), 134.8 (C-10), 174.5 (C-1), 208.8 (C-18), 215.3 (C-13); HR-ESI-MS m/z 461.2898 $[\text{M} + \text{Na}]^+$ (calc. for $\text{C}_{25}\text{H}_{42}\text{O}_6\text{Na}$, 461.2874).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Large thanks to our long standing collaborator, Dr. Rob W. M. van Soest, for his expertise with sponge taxonomy. Funding for these projects is provided by the Sandler Family Foundation, the National Institutes of Health (RO1 CA052855 and U01 AI075641), the NIGMS (MBRS GM058903), and the California Institute for Quantitative Biosciences. We also thank Dr. W. Inman for his insightful conversations and support of this study, the Captain and Crew of the *M/V Golden Dawn* for their assistance in sponge collection, and Dr. T. Matainaho of the University of Papua New Guinea for his assistance with collection permits.

References and Notes

1. World Health Organization: Human African Trypanosomiasis. Sept 12. 2008
http://www.who.int/trypanosomiasis_african/en/index.html
2. Mallari JP, Shelat AA, O'Brien T, Caffrey CR, Kosinski A, Connelly M, Harbut M, Greenbaum D, McKerrow JH, Guy RK. *J Med Chem* 2008;51:545–552. [PubMed: 18173229]
3. Kennedy PG. *Annal Neurol* 2008;64:116–126. [PubMed: 18756506]
4. Barrett MP, Boykin DW, Brun R, Tidwell RR. *Br J Pharmacol* 2007;152:1155–1171. [PubMed: 17618313]
5. Mallari JP, Shelat A, Kosinski A, Caffrey CR, Connelly M, Zhu F, McKerrow JH, Guy RK. *Bioorg Med Chem Lett* 2008;18:2883–2885. [PubMed: 18420405]
6. de Koning HP. *Trends Parasitol* 2008;24:345–349. [PubMed: 18599351]
7. Das BP, Boykin DW. *J Med Chem* 1977;20:531–536. [PubMed: 321783]
8. Crews, P.; Hunger, TM. *Marine Biotechnology*. In: Attaway, DH.; Zaborsky, OR., editors. *Pharmaceutical and Bioactive Natural Products*. Vol. 1. Plenum Press; New York: 1993. p. 343–389.
9. a) Quinoa E, Crews P. *Tetrahedron Lett* 1987;28:3229–3232. b) Arabshahi L, Schmitz FJ. *J Org Chem* 1987;52:3584–3586.
10. Urbaniak MD, Tabudravu JN, Msaki A, Matera KM, Brenk R, Jaspars M, Ferguson MA. *Bioorg Med Chem Lett* 2006;16:5744–1547. [PubMed: 16962325]
11. The term “peroxiterpene” derived from “peroxide” and “terpene” is defined here for the first time. It unifies a growing class of stable, often bioactive, terpenes possessing such functionality.
12. a) Sperry S, Valeriote FA, Corbett TH, Crews P. *J Nat Prod* 1998;61:241–247. [PubMed: 9514009]
b) Ibrahim SRM, Ebel R, Wray V, Mueller WEG, Edrada-Ebel R, Proksch P. *J Nat Prod* 2008;71:1358–1364. [PubMed: 18672931]
13. El Sayed KA, Hamann MT, Hashish NE, Shier WT, Kelly M, Khan AA. *J Nat Prod* 2001;64:522–524. [PubMed: 11325240]
14. Youssef DTA, Yoshida WY, Kelly M, Scheuer PJ. *J Nat Prod* 2001;64:1332–1335. [PubMed: 11678661]
15. Albericci M, Collartlempereur M, Braekman JC, Daloze D, Tursch B, Declercq JP, Germain G, Vanmeerssche M. *Tetrahedron Lett* 1979;20:2687–2690.
16. Albericci M, Braekman JC, Daloze D, Tursch B. *Tetrahedron* 1982;38:1881–1890.
17. vanSoestRWM, Boury-EsnaultNH, CooperJN, RützlerK, de VoogdNJ, AlvarezBH, AdjuEP, SieraAB, VaceletJ, ManconiRS, SchoenbergC, JanussenD, TabanickKR, KlautauM. 2008 World Porifera Database Available online at <http://www.marinespecies.org/porifera>. Consulted on 2008-10-19b) According to the World Porifera Database, sponges classified as *Sigmosceptrella laevis* are now accepted as *Diacarnus laevis*.
18. Capon RJ, Macleod JK. *Tetrahedron* 1985;41:3391–3404.
19. Crews, P.; Rodriguez, J.; Jaspars, M. *Organic Structure Analysis*. Oxford University Press, Inc; New York, NY: 1998.
20. Kuehnle E, Laffan DDR, Lloyd-Jones GC, del Campo TM, Shepperson IR, Slaughter JL. *Angew Chem, Int Ed* 2007;46:7075–7078.

21. Yanai M, Ohta S, Ohta E, Hirata T, Ikegami S. *Bioorg Med Chem* 2003;11:1715–1721. [PubMed: 12659758]
22. Ohtani I, Kusumi T, Kashman Y, Kakisawa H. *J Am Chem Soc* 1991;113:4092–4096.
23. a) D'Ambrosio M, Guerriero A, Deharo E, Debitus C, Munoz V, Pietra F. *Helv Chim Acta* 1998;81:1285–1292. b) Ovenden SPB, Capon RJ. *J Nat Prod* 1999;62:214–218. [PubMed: 10075744] c) Phuwapraisirisan P, Matsunaga S, Fusetani N, Chaitanawisuti N, Kritsanapuntu S, Menasveta P. *J Nat Prod* 2003;66:289–291. [PubMed: 12608869] d) Tanaka J, Higa T, Suwanborirux K, Kokpol U, Bernardinelli G, Jefford CW. *J Org Chem* 1993;58:2999–3002. e) Capon RJ, Macleod JK, Coote SJ, Davies SG, Gravatt GL, Dordorhedgecock IM, Whittaker M. *Tetrahedron* 1988;44:1637–1650. f) Capon RJ, Macleod JK, Willis AC. *J Org Chem* 1987;52:339–342.
24. Kossuga MH, Nascimento AM, Reimao JQ, Tempone AG, Taniwaki NN, Veloso K, Ferreira AG, Cavalcanti BC, Pessoa C, Moraes MO, Mayer AMS, Hajdu E, Berlinck RGS. *J Nat Prod* 2008;71:334–339. [PubMed: 18177008]
25. Lim CW, Kim YK, Youn HD, Park HY. *Agric Chem Biotechnol (Engl Ed)* 2006;49:21–23.
26. Kaiser M, Wittlin S, Nehrbass-Stuedli A, Dong Y, Wang X, Hemphill A, Matile H, Brun R, Vennerstrom JL. *Antimicrob Agents Chemother* 2007;51:2991–2993. [PubMed: 17562801]
27. Mishina YV, Krishna S, Haynes RK, Meade JC. *Antimicrob Agents Chemother* 2007;51:1852–1854. [PubMed: 17339374]





Figure 1.
Key 2D NMR correlations for (+)-muqubilone B (**1a**).

**Scheme 1.**

Modified Mosher's method analysis of (+)-muqubilone B (**1a**). i) TMS-CHN₂ (2M in hexanes), CH₃OH, r.t., 30 min.; ii) H₂ (1atm), Pd/C, EtOH, r.t., 1 hr; iii) (+)- or (-)-MTPA-Cl, pyr., r.t., 18 hr.

Table 1NMR Data for (+)-Muqubilone B (**1a**) in CDCl₃^a

Position	δ_C , type	δ_H , mult. (<i>J</i> in Hz)	HMBC (H to C)	COSY
1	178.6, C	-		
2	42.4, CH	2.55, quint. (7.2)	3, 20	3, 20
3	81.2, CH	4.25, ddd (8.4, 7.2, 4.2)		2, 4
4ax	23.8, CH ₂	1.77, dtd (12.0, 8.4, 4.2)	21	5
4eq		1.70, dtd (12.0, 4.2, 3)	3	3
5	32.5, CH ₂	1.66, m	6, 21	4
6	80.0, C	-		
7	34.7, CH ₂	1.49, m	21	8
8a	22.0, CH ₂	2.04, m		7, 9
8b		1.94, m		
9	124.6, CH	5.16, td (7.2, 1.2)		8
10	134.4, C	-		
11	33.4, CH ₂	2.21, t (7.8)	9, 10, 12, 22	12
12	35.6, CH ₂	2.56, t (7.8)	10, 11, 13	11
13	215.4, C	-		
14	47.5, C	-		
15a	39.1, CH ₂	1.51, m	16	16
15b		1.46, m		
16	18.9, CH ₂	1.42, m	15	15, 17
17	43.9, CH ₂	2.42, t (7.2)	16, 18	16
18	209.1, C	-		
19	29.8, CH ₃	2.14, s	17, 18	
20	12.7, CH ₃	1.20, d (7.2)	1, 2, 3	2
21	22.6, CH ₃	1.12, s	4, 5, 6, 8	
22	16.0, CH ₃	1.62, d (1.2)	9, 10, 11	
23,24	24.3, CH ₃	1.13, s	13, 14, 15	
OH	-	3.71, s	1	

^aMeasured at 600 MHz (¹H) and 150 MHz (¹³C).